BlackRock Fund Advisors has recently announced that it has increased stake in Infinity Pharmaceuticals Inc. (NASDAQ:INFI) by 0.02%. After grabbing 1.45 million shares, the institutional investor is now in possession of 352.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 1.62% having worth around $0.18 million. Moreover, Carlson Capital LP increased its share by 0.3 million to have a control over 1.3 million shares. And Mariner LLC raised its holdings to 1.2 million shares by acquiring 1.2 million shares or 1.33% of the stake.
Infinity Pharmaceuticals Inc. (INFI) concluded trading on 09/13/23 at a closing price of $0.04, with 21.21 million shares of worth about $0.85 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -76.47% during that period and on Wednesday the price saw a loss of about -46.98%. Currently the company’s common shares owned by public are about 89.89M shares, out of which, 88.64M shares are available for trading.
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 1 analysts are covering the INFI stock and their offered price forecasts bring an average price target of $0.30. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $0.30 and could fall to a lowest price of $0.30. However, touching the estimated high of $0.30 would mean a gain of 86.67% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 0 times over the past 12 months. They bought 0 shares in 0 of the transactions. In 0 selling transactions, insiders dumped 0 shares.
Vanguard Total Stock Market ETF, Vanguard Extended Market Index Fu, and Fidelity Extended Market Index Fu are the top 3 mutual funds which are holding stakes in Infinity Pharmaceuticals Inc. Vanguard Total Stock Market ETF is currently holding 2.56 million shares of worth totaling $0.32 million. The company recently came buying 0.0 shares which brought its stake up to 2.84% of the company’s outstanding shares. Fidelity Extended Market Index Fu, after buying 0.47 million shares, have now control over 0.52% of the stake in the company. It holds 0.0 shares of worth $59799.0.
Infinity Pharmaceuticals Inc. (NASDAQ: INFI) started trading at $0.0745, below -$0.01 from concluding price of the previous day. However, the stock later moved at a day high price of 0.0800, or with a loss of -46.98%. Stock saw a price change of -49.49% in past 5 days and over the past one month there was a price change of -54.39%. Year-to-date (YTD), INFI shares are showing a performance of -91.95% which decreased to -96.85% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.07 but also hit the highest price of $1.47 during that period. The average intraday trading volume for Infinity Pharmaceuticals Inc. shares is 3.51 million. The stock is currently trading -50.56% below its 20-day simple moving average (SMA20), while that difference is down -66.74% for SMA50 and it goes to -84.70% lower than SMA200.
BlackRock Fund Advisors acquired 1.45 million shares of Infinity Pharmaceuticals Inc. having value of about $0.18 million. Data submitted at the U.S SEC by BlackRock Fund Advisors revealed that the firm now holds 352.0 shares in the company valued at close to $14.08, or have control over 0.02% stake in the company. Infinity Pharmaceuticals Inc. (NASDAQ: INFI) currently have 89.89M outstanding shares and institutions hold larger chunk of about 35.70% of that. Holding of mutual funds in the company is about 22.57% while other institutional holders and individual stake holders have control over 6.17% and 16.54% of the stake respectively.
The stock has a current market capitalization of $4.37M and its 3Y-monthly beta is at 1.39. It has posted earnings per share of -$0.46 in the same period. It has Quick Ratio of 1.70. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for INFI, volatility over the week remained 38.76% while standing at 20.63% over the month.
Analysts are in expectations that Infinity Pharmaceuticals Inc. (INFI) stock would likely to be making an EPS of $0 in the current quarter, while forecast for next quarter EPS is $0 and it is $0 for next year. For the current quarter EPS, analysts have given the company a lowest target $0 which is $0 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.13 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 6.00% while it is estimated to decrease by -19.60% in next year.
Analysts at 1 brokerage firms have issued recommendations for the Infinity Pharmaceuticals Inc. (INFI)’s stock and average of those rates the stock at a “Hold” and assign it a score of 3.00. Out of those 1 Wall Street analysts, 0 recommended a “Buy” rating, while 1 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on October 18, 2021 offering a Buy rating for the stock and assigned a target price of $9 to it.